SCHEMBL11890771

SCHEMBL11890771

COc1ccc(CNc2ccc(C(C)=O)cc2N)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 3/20 0.53
PRKCI P41743 1/20 0.52
VNN1 O95497 3/20 0.49
HDAC3 O15379 2/20 0.48
HDAC2 Q92769 2/20 0.48
NCOR2 Q9Y618 1/20 0.48
AKR1C3 P42330 1/20 0.48
AKR1C2 P52895 1/20 0.48
KDM4E B2RXH2 2/20 0.47
ASPH Q12797 1/20 0.47
RIOX2 Q8IUF8 1/20 0.47
KDM8 Q8N371 1/20 0.47
ALDH1A1 P00352 2/20 0.47
MAPT P10636 2/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
PTGER4 P35408 1/20 0.47
GSK3B P49841 2/20 0.46
GAA P10253 2/20 0.46
THRB P10828 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12004538 0.90 GAA (0.54) HDAC1VNN1HDAC3HDAC2NCOR2
SCHEMBL18995963 0.90 HDAC1 (0.56) HDAC1VNN1HDAC3HDAC2NCOR2
SCHEMBL12061580 0.87 HDAC1 (0.51) HDAC1VNN1HDAC3HDAC2NCOR2
SCHEMBL9725455 0.85 VNN1 (0.57) HDAC1VNN1HDAC3HDAC2NCOR2
SCHEMBL11754772 0.84 KDM4E (0.49) HDAC1VNN1HDAC3HDAC2NCOR2
SCHEMBL14402 0.80 AKR1C3 (0.57) AKR1C3AKR1C2MAPTMEN1KMT2A
SCHEMBL14565802 0.80 FFAR1 (0.51) HDAC1HDAC3HDAC2NCOR2KDM4E
SCHEMBL7871463 0.79 HDAC1 (0.56) HDAC1VNN1HDAC3HDAC2NCOR2
SCHEMBL9683331 0.78 MAP2K4 (0.52) HDAC1MAPTMEN1KMT2AGAA
SCHEMBL9683167 0.78 HTT (0.51) VNN1MAPTMEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170174704-A1 QUINOXALINE COMPOUNDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2017-06-22 US disclosed
US-8563543-B2 Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use MERCK SHARP & DOHME CORP. (US) 2013-10-22 US disclosed
US-20120189642-A1 IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE SCHERING CORPORATION (US) 2012-07-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170174704-A1 QUINOXALINE COMPOUNDS AND USES THEREOF NAMPT, NQO2, NNMT HDAC1 987/4885PRKCI 3676/4885VNN1 758/4885
US-20120189642-A1 IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE BACE1, APP, BACE2 HDAC1 3413/4885PRKCI 2857/4885VNN1 3248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.